Novo Nordisk A/S (NVO) — closed signal from May 20, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on August 18, 2026.
Predicted vs. what happened
NVO price · publication thesis → realized outcomesplit-adjusted
$42.41 – $44.12Entry zone — fair-value band
$44.36Published — price the day we called it
$46.87Target — the price the thesis aimed for
$51.46Peak — highest point inside the window, not a realized return
$45.71Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 36 days.
Peak price
$51.46
peak on July 29, 2026 — not a realized returnPeak gain
+16%
peak, from the publication priceWindow close
$45.71
end-of-window price, context onlyDays to target
36
Window
May 20, 2026 – August 18, 2026
The thesis — published May 20, 2026
Predicted growth
+7%
over the measurement windowTarget price
$46.87
the price the thesis aimed forEntry zone
$42.41 – $44.12
the fair-value band we waited forPrice at publication
$44.36
published May 20, 2026Confidence
69%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Novo Nordisk is a steady health-care company led by its diabetes and obesity medicines. New trial coverage for Wegovy and a share buyback have calmed investors, but rivals in the GLP-1 space and weak price momentum limit short-term gains. Near current support, expected upside in the next few months is cautious, not aggressive.
Primary drivers
- GLP-1 drugs drive the company's future sales and growth
- Share buybacks make the stock more attractive to investors
- Stable health-care business helps in volatile markets
- Rising competition keeps expectations for gains modest
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.